XERS Relative Valuation
XERS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XERS is overvalued; if below, it's undervalued.
Historical Valuation
Xeris Biopharma Holdings Inc (XERS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -8.11. The fair price of Xeris Biopharma Holdings Inc (XERS) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：6.72
Fair
55.22
PE
1Y
3Y
5Y
Trailing
Forward
22.31
EV/EBITDA
Xeris Biopharma Holdings Inc. (XERS) has a current EV/EBITDA of 22.31. The 5-year average EV/EBITDA is -14.64. The thresholds are as follows: Strongly Undervalued below -235.95, Undervalued between -235.95 and -125.29, Fairly Valued between 96.02 and -125.29, Overvalued between 96.02 and 206.67, and Strongly Overvalued above 206.67. The current Forward EV/EBITDA of 22.31 falls within the Historic Trend Line -Fairly Valued range.
30.22
EV/EBIT
Xeris Biopharma Holdings Inc. (XERS) has a current EV/EBIT of 30.22. The 5-year average EV/EBIT is -2.03. The thresholds are as follows: Strongly Undervalued below -93.07, Undervalued between -93.07 and -47.55, Fairly Valued between 43.50 and -47.55, Overvalued between 43.50 and 89.02, and Strongly Overvalued above 89.02. The current Forward EV/EBIT of 30.22 falls within the Historic Trend Line -Fairly Valued range.
3.13
PS
Xeris Biopharma Holdings Inc. (XERS) has a current PS of 3.13. The 5-year average PS is 2.14. The thresholds are as follows: Strongly Undervalued below 0.63, Undervalued between 0.63 and 1.39, Fairly Valued between 2.89 and 1.39, Overvalued between 2.89 and 3.65, and Strongly Overvalued above 3.65. The current Forward PS of 3.13 falls within the Overvalued range.
265.87
P/OCF
Xeris Biopharma Holdings Inc. (XERS) has a current P/OCF of 265.87. The 5-year average P/OCF is 73.26. The thresholds are as follows: Strongly Undervalued below -581.24, Undervalued between -581.24 and -253.99, Fairly Valued between 400.52 and -253.99, Overvalued between 400.52 and 727.77, and Strongly Overvalued above 727.77. The current Forward P/OCF of 265.87 falls within the Historic Trend Line -Fairly Valued range.
398.81
P/FCF
Xeris Biopharma Holdings Inc. (XERS) has a current P/FCF of 398.81. The 5-year average P/FCF is -8.08. The thresholds are as follows: Strongly Undervalued below -334.49, Undervalued between -334.49 and -171.29, Fairly Valued between 155.12 and -171.29, Overvalued between 155.12 and 318.33, and Strongly Overvalued above 318.33. The current Forward P/FCF of 398.81 falls within the Strongly Overvalued range.
Xeris Biopharma Holdings Inc (XERS) has a current Price-to-Book (P/B) ratio of -1292.06. Compared to its 3-year average P/B ratio of -108.26 , the current P/B ratio is approximately 1093.44% higher. Relative to its 5-year average P/B ratio of -80.22, the current P/B ratio is about 1510.70% higher. Xeris Biopharma Holdings Inc (XERS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -17.95%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -24.91% , the current FCF yield is about -100.00% lower.
-1292.06
P/B
Median3y
-108.26
Median5y
-80.22
0.89
FCF Yield
Median3y
-17.95
Median5y
-24.91
Competitors Valuation Multiple
The average P/S ratio for XERS's competitors is 0.00, providing a benchmark for relative valuation. Xeris Biopharma Holdings Inc Corp (XERS) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 37.06%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of XERS increased by 98.23% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -24.38 to -64.37.
The secondary factor is the Revenue Growth, contributed 37.06%to the performance.
Overall, the performance of XERS in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Xeris Biopharma Holdings Inc (XERS) currently overvalued or undervalued?
What is Xeris Biopharma Holdings Inc (XERS) fair value?
How does XERS's valuation metrics compare to the industry average?
What is the current P/B ratio for Xeris Biopharma Holdings Inc (XERS) as of Dec 05 2025?
What is the current FCF Yield for Xeris Biopharma Holdings Inc (XERS) as of Dec 05 2025?
What is the current Forward P/E ratio for Xeris Biopharma Holdings Inc (XERS) as of Dec 05 2025?